We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

NextGen Sciences to Develop and Validate Protein Biomarker Assays for Takeda Pharmaceuticals


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NextGen Sciences to Develop and Validate Protein Biomarker Assays for Takeda Pharmaceuticals"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

The biomarker assays will be designed to target specific protein isoforms found in liver and muscle in multiple species, for use in preclinical studies, and will also be validated for use in clinical studies. NextGen Sciences’ Multiple Reaction Monitoring (MRM) protein assay platform is ideal for studies of this kind, which involve multiple isoforms and multiple species.

Dr Michael Pisano, CEO of NextGen Sciences, commented: “We are delighted to have been chosen for this project and look forward to working closely with Takeda’s scientists in Japan.”

Advertisement